ArticleJournal of veterinary science2026
Antiplatelet effect of spironolactone via modulation of cPLA₂-mediated thromboxane A₂ generation in murine platelets.
Article in Journal of veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
importanceSpironolactone, a steroidal aldosterone antagonist, is widely used as a diuretic and antihypertensive agent. Steroids have been known to promote thrombosis by directly increasing platelet count and activation and indirectly by increasing oxidative stress and suppressing nitric oxide synthesis. However, the effects of spironolactone on platelet activation remain unclear.
objectiveTo investigate the effects of spironolactone on platelet function and underlying signaling mechanisms.
methodsPlatelet aggregation, dense granule secretion, thromboxane A₂ (TxA₂) generation, and protein phosphorylation were evaluated in platelets treated with spironolactone.
resultsSpironolactone significantly inhibited the secondary wave of platelet aggregation and dense granule secretion induced by 2-methylthioadenosine diphosphate (2-MeSADP). It is known that 2-MeSADP-induced secretion and the resultant secondary wave of aggregation depend on TxA₂-mediated positive feedback, suggesting a role for spironolactone in regulating TxA₂ generation in platelets. Additionally, spironolactone did not affect 2-MeSADP-induced platelet aggregation in aspirin-treated platelets in which TxA₂ generation was blocked. Furthermore, platelet aggregation and secretion induced by low concentrations of thrombin, which are also affected by TxA₂-mediated positive feedback, were partially inhibited by spironolactone. Notably, spironolactone significantly suppressed TxA₂ generation induced by both 2-MeSADP and thrombin. Finally, spironolactone markedly inhibited the 2-MeSADP- and thrombin-induced phosphorylation of cytosolic phospholipase A₂ (cPLA₂), extracellular signal-regulated kinase, and protein kinase B in non-aspirin-treated platelets, whereas only cPLA₂ phosphorylation was significantly inhibited in aspirin-treated platelets. CONCLUSIONS AND RELEVANCE: Spironolactone inhibits platelet activation by suppressing TxA₂ generation, primarily by modulating cPLA₂ phosphorylation, providing mechanistic insight into its effects on platelet signaling
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.